| Species Reactivity | Human |
| Clone | pumitamig |
| Source/Isotype | Human IgG1(L234A/L235A) ,Kappa |
| Application | Block assay |
| Target | Detects VEGF & PD-L1 |
| Gene | VEGF & PD-L1 |
| Other Names | VEGF: KDR,CD309,FLK1,VEGF R2 PD-L1: CD274,B7-H1,PDCD1L1,PDCD1LG1,B7H1, PDL1, hPD-L1 |
| Gene ID | VEGF: 7422 (Human) PD-L1: 29126 (Human) |
| Background | Pumitamig (BNT327) is a bispecific antibody drug that targets PD-L1 and VEGF-A in a research context derived from the unmet need that exists in the treatment of solid tumors such as small-cell carcinoma (SCLC) . As a highly malignant subtype of lung cancer, SCLC has the characteristics of rapid growth and easy metastasis. About 70% of patients are in an extensive stage when they are diagnosed. Traditional treatment methods have limited effect, and the 5-year survival rate has been low for a long time. PD-L1 promotes immune escape by inhibiting immune cell function in the tumor microenvironment, while VEGF-A supports tumor growth and metastasis by driving tumor angiogenesis. By simultaneously blocking these two key targets, Pumitamig aims to restore effector T cell activity, inhibit tumor angiogenesis, and break the tumor immune escape mechanism to achieve a multidimensional attack on tumors. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human |
| Clone | pumitamig |
| Source/Isotype | Human IgG1(L234A/L235A) ,Kappa |
| Application | Block assay |
| Target | Detects VEGF & PD-L1 |
| Gene | VEGF & PD-L1 |
| Other Names | VEGF: KDR,CD309,FLK1,VEGF R2 PD-L1: CD274,B7-H1,PDCD1L1,PDCD1LG1,B7H1, PDL1, hPD-L1 |
| Gene ID | VEGF: 7422 (Human) PD-L1: 29126 (Human) |
| Background | Pumitamig (BNT327) is a bispecific antibody drug that targets PD-L1 and VEGF-A in a research context derived from the unmet need that exists in the treatment of solid tumors such as small-cell carcinoma (SCLC) . As a highly malignant subtype of lung cancer, SCLC has the characteristics of rapid growth and easy metastasis. About 70% of patients are in an extensive stage when they are diagnosed. Traditional treatment methods have limited effect, and the 5-year survival rate has been low for a long time. PD-L1 promotes immune escape by inhibiting immune cell function in the tumor microenvironment, while VEGF-A supports tumor growth and metastasis by driving tumor angiogenesis. By simultaneously blocking these two key targets, Pumitamig aims to restore effector T cell activity, inhibit tumor angiogenesis, and break the tumor immune escape mechanism to achieve a multidimensional attack on tumors. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
